Analysts’ Price Target Changes for November 4th (AHCO, ATRC, BEAM, BNTX, CBLL, CBT, CC, DOCN, DT, EME)

Analysts’ price target changes for Wednesday, November 4th:

AdaptHealth (NASDAQ:AHCO) had its target price reduced by UBS Group from $10.00 to $9.00. UBS Group currently has a buy rating on the stock.

AtriCure (NASDAQ:ATRC) had its target price boosted by Canaccord Genuity Group from $55.00 to $67.00. They currently have a buy rating on the stock.

Beam Therapeutics (NASDAQ:BEAM) had its target price cut by Canaccord Genuity Group from $79.00 to $78.00. Canaccord Genuity Group currently has a buy rating on the stock.

BioNTech (NASDAQ:BNTX) had its price target trimmed by UBS Group from $135.00 to $125.00. The firm currently has a buy rating on the stock.

CeriBell (NASDAQ:CBLL) had its price target raised by Canaccord Genuity Group from $26.00 to $33.00. They currently have a buy rating on the stock.

Cabot (NYSE:CBT) had its price target trimmed by UBS Group from $86.00 to $80.00. The firm currently has a neutral rating on the stock.

Chemours (NYSE:CC) had its target price lowered by UBS Group from $16.00 to $15.00. They currently have a neutral rating on the stock.

DigitalOcean (NYSE:DOCN) had its price target lowered by UBS Group from $105.00 to $100.00. UBS Group currently has a neutral rating on the stock.

DigitalOcean (NYSE:DOCN) had its price target cut by Canaccord Genuity Group from $200.00 to $180.00. They currently have a buy rating on the stock.

Dynatrace (NYSE:DT) had its price target lowered by UBS Group from $80.00 to $75.00. UBS Group currently has a buy rating on the stock.

EMCOR Group (NYSE:EME) had its price target reduced by UBS Group from $1,065.00 to $925.00. UBS Group currently has a buy rating on the stock.

Freshworks (NASDAQ:FRSH) had its price target raised by Canaccord Genuity Group from $15.00 to $17.00. The firm currently has a buy rating on the stock.

Hillman Solutions (NASDAQ:HLMN) had its price target lowered by Canaccord Genuity Group from $13.00 to $12.00. The firm currently has a buy rating on the stock.

HealthStream (NASDAQ:HSTM) had its target price raised by Canaccord Genuity Group from $29.00 to $32.00. Canaccord Genuity Group currently has a hold rating on the stock.

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price raised by Canaccord Genuity Group from $612.00 to $633.00. The firm currently has a buy rating on the stock.

AG Mortgage Investment Trust (NYSE:MITT) had its target price lowered by JonesTrading from $8.00 to $7.00. The firm currently has a buy rating on the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by Canaccord Genuity Group from $39.00 to $34.00. They currently have a buy rating on the stock.

Revolve Group (NYSE:RVLV) had its price target cut by UBS Group from $27.00 to $26.00. They currently have a neutral rating on the stock.

Sprout Social (NASDAQ:SPT) had its target price boosted by Canaccord Genuity Group from $10.00 to $13.50. Canaccord Genuity Group currently has a hold rating on the stock.

Silver Standard Resources (NASDAQ:SSRM) (TSE:SSO) had its price target reduced by UBS Group from $39.00 to $37.00. The firm currently has a buy rating on the stock.

Stevanato Group (NYSE:STVN) had its target price cut by UBS Group from $23.00 to $16.00. The firm currently has a neutral rating on the stock.

Grupo Televisa (NYSE:TV) had its target price cut by UBS Group from $3.20 to $2.30. UBS Group currently has a neutral rating on the stock.

Travere Therapeutics (NASDAQ:TVTX) had its price target increased by Canaccord Genuity Group from $70.00 to $72.00. Canaccord Genuity Group currently has a buy rating on the stock.

Xometry (NASDAQ:XMTR) had its price target increased by UBS Group from $95.00 to $108.00. They currently have a neutral rating on the stock.